{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:16:30Z","timestamp":1785575790799,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T00:00:00Z","timestamp":1408492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/ejhg.2014.161","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T10:24:06Z","timestamp":1408530246000},"page":"588-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of the Dutch BRCA1\/2 clinical genetic center referral criteria in an unselected early breast cancer population"],"prefix":"10.1038","volume":"23","author":[{"given":"Alexandra J","family":"van den Broek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"de Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J","family":"van 't Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A E M","family":"Tollenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senno","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjanka K","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"key":"BFejhg2014161_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117\u20131130.","journal-title":"Am J Hum Genet"},{"key":"BFejhg2014161_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE 4. J Natl Cancer Inst 2013; 105: 812\u2013822.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg2014161_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/jmedgenet-2013-101974","volume":"51","author":"RM Brohet","year":"2014","unstructured":"Brohet RM, Velthuizen ME, Hogervorst FB et al: Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations 1. J Med Genet 2014; 51: 98\u2013107.","journal-title":"J Med Genet"},{"key":"BFejhg2014161_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB : Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643\u2013646.","journal-title":"Science"},{"key":"BFejhg2014161_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329\u20131333.","journal-title":"J Clin Oncol"},{"key":"BFejhg2014161_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","volume":"43","author":"FP Liebens","year":"2007","unstructured":"Liebens FP, Carly B, Pastijn A, Rozenberg S : Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007; 43: 238\u2013257.","journal-title":"Eur J Cancer"},{"key":"BFejhg2014161_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ijc.22817","volume":"121","author":"MJ Bermejo-Perez","year":"2007","unstructured":"Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A : Effectiveness of preventive interventions in BRCA1\/2 gene mutation carriers: a systematic review. Int J Cancer 2007; 121: 225\u2013231.","journal-title":"Int J Cancer"},{"key":"BFejhg2014161_CR8","first-page":"1","volume":"16","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Rebbeck TR : Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. LDI Issue Brief 2010; 16: 1\u20134.","journal-title":"LDI Issue Brief"},{"key":"BFejhg2014161_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg2014161_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrclinonc.2010.166","volume":"7","author":"SA Narod","year":"2010","unstructured":"Narod SA : BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol 2010; 7: 702\u2013707.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFejhg2014161_CR11","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2174\/138945011798829438","volume":"12","author":"SK Sandhu","year":"2011","unstructured":"Sandhu SK, Yap TA, de Bono JS : The emerging role of poly(ADP-ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets 2011; 12: 2034\u20132044.","journal-title":"Curr Drug Targets"},{"key":"BFejhg2014161_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","volume":"46","author":"SK Sandhu","year":"2010","unstructured":"Sandhu SK, Yap TA, de Bono JS : Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010; 46: 9\u201320.","journal-title":"Eur J Cancer"},{"key":"BFejhg2014161_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.genet.32.1.95","volume":"32","author":"N Rahman","year":"1998","unstructured":"Rahman N, Stratton MR : The genetics of breast cancer susceptibility. Annu Rev Genet 1998; 32: 95\u2013121.","journal-title":"Annu Rev Genet"},{"key":"BFejhg2014161_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","volume":"9","author":"D Thompson","year":"2004","unstructured":"Thompson D, Easton D : The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9: 221\u2013236.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"Suppl 1","key":"BFejhg2014161_CR15","doi-asserted-by":"publisher","first-page":"i60","DOI":"10.1093\/annonc\/mdq668","volume":"22","author":"A Surbone","year":"2011","unstructured":"Surbone A : Social and ethical implications of BRCA testing. Ann Oncol 2011; 22 (Suppl 1): i60\u2013i66.","journal-title":"Ann Oncol"},{"key":"BFejhg2014161_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12687-011-0042-4","volume":"2","author":"D Gadzicki","year":"2011","unstructured":"Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial\/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53\u201369.","journal-title":"J Community Genet"},{"key":"BFejhg2014161_CR17","unstructured":"NABON. CBO (Dutch Institute for Healthcare Improvement) guideline for breast cancer; 2012 Available at: \n                    http:\/\/www.oncoline.nl\/mammacarcinoom\n                    \n                   (last accessed on 26 June 2014)."},{"key":"BFejhg2014161_CR18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jmg.2009.067850","volume":"46","author":"DG Evans","year":"2009","unstructured":"Evans DG, Lalloo F, Cramer A et al: Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009; 46: 811\u2013817.","journal-title":"J Med Genet"},{"key":"BFejhg2014161_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2407-9-86","volume":"9","author":"SR Young","year":"2009","unstructured":"Young SR, Pilarski RT, Donenberg T et al: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009; 9: 86.","journal-title":"BMC Cancer"},{"key":"BFejhg2014161_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","volume":"145","author":"P Sharma","year":"2014","unstructured":"Sharma P, Klemp JR, Kimler BF et al: Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing 3. Breast Cancer Res Treat 2014; 145: 707\u2013714.","journal-title":"Breast Cancer Res Treat"},{"key":"BFejhg2014161_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/sj.bjc.6603358","volume":"95","author":"HH Kang","year":"2006","unstructured":"Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R : Evaluation of models to predict BRCA germline mutations. Br J Cancer 2006; 95: 914\u2013920.","journal-title":"Br J Cancer"},{"key":"BFejhg2014161_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJM199705153362002","volume":"336","author":"FJ Couch","year":"1997","unstructured":"Couch FJ, DeShano ML, Blackwood MA et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409\u20131415.","journal-title":"N Engl J Med"},{"key":"BFejhg2014161_CR23","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480\u20131490.","journal-title":"J Clin Oncol"},{"key":"BFejhg2014161_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O : Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145\u2013158.","journal-title":"Am J Hum Genet"},{"key":"BFejhg2014161_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1136\/jmg.2003.017996","volume":"41","author":"DG Evans","year":"2004","unstructured":"Evans DG, Eccles DM, Rahman N et al: A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004; 41: 474\u2013480.","journal-title":"J Med Genet"},{"key":"BFejhg2014161_CR26","unstructured":"Schmidt MK et alBRCA1 and BRCA2 mutation spectrum in a hospital-based series of young breast cancer patients (unpublished)."},{"key":"BFejhg2014161_CR27","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC : Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474\u20131481.","journal-title":"J Clin Oncol"},{"key":"BFejhg2014161_CR28","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM : Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155\u2013168.","journal-title":"Mod Pathol"},{"key":"BFejhg2014161_CR29","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ejca.2009.03.008","volume":"45","author":"MK Schmidt","year":"2009","unstructured":"Schmidt MK, Vermeulen E, Tollenaar RA, Van't Veer LJ, van Leeuwen FE : Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding. Eur J Cancer 2009; 45: 2376\u20132382.","journal-title":"Eur J Cancer"},{"key":"BFejhg2014161_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djq088","volume":"102","author":"E Amir","year":"2010","unstructured":"Amir E, Freedman OC, Seruga B, Evans DG : Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010; 102: 680\u2013691.","journal-title":"J Natl Cancer Inst"},{"key":"BFejhg2014161_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/modpathol.3800453","volume":"18","author":"E Honrado","year":"2005","unstructured":"Honrado E, Benitez J, Palacios J : The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005; 18: 1305\u20131320.","journal-title":"Mod Pathol"},{"key":"BFejhg2014161_CR32","unstructured":"STOET-VGKN. Dutch CGC referral criteria (Stichting Opsporing Erfelijke Tumoren \u2013Vereniging Klinische Genetica Nederland (STOET-VGKN) criteria), edition 1996 and 2001."},{"key":"BFejhg2014161_CR33","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/GIM.0b013e318159a318","volume":"9","author":"KJ Schlich-Bakker","year":"2007","unstructured":"Schlich-Bakker KJ, ten Kroode HF, Warlam-Rodenhuis CC, van den Bout J, Ausems MG : Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer. Genet Med 2007; 9: 766\u2013777.","journal-title":"Genet Med"},{"key":"BFejhg2014161_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2354.2008.01065.x","volume":"19","author":"E Van Riel","year":"2010","unstructured":"Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG : BRCA testing of breast cancer patients: medical specialists\u2019 referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 2010; 19: 369\u2013376.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"BFejhg2014161_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/14796694.2.2.257","volume":"2","author":"AC Antoniou","year":"2006","unstructured":"Antoniou AC, Easton DF : Risk prediction models for familial breast cancer. Fut Oncol 2006; 2: 257\u2013274.","journal-title":"Fut Oncol"},{"key":"BFejhg2014161_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-010-1137-z","volume":"127","author":"C Bouchardy","year":"2011","unstructured":"Bouchardy C, Benhamou S, Fioretta G et al: Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 2011; 127: 233\u2013241.","journal-title":"Breast Cancer Res Treat"},{"key":"BFejhg2014161_CR37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.ejca.2005.02.030","volume":"41","author":"CC Warlam-Rodenhuis","year":"2005","unstructured":"Warlam-Rodenhuis CC, Koot VC, van der Luijt RB, Vasen HF, Ausems MG : A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients. Eur J Cancer 2005; 41: 1409\u20131415.","journal-title":"Eur J Cancer"},{"key":"BFejhg2014161_CR38","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J et al: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310\u20132318.","journal-title":"J Clin Oncol"},{"key":"BFejhg2014161_CR39","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon JS, Gutierrez-Barrera AM, Young D et al: Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010; 28: 4214\u20134220.","journal-title":"J Clin Oncol"},{"key":"BFejhg2014161_CR40","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bjc.2012.31","volume":"106","author":"L Robertson","year":"2012","unstructured":"Robertson L, Hanson H, Seal S et al: BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer 2012; 106: 1234\u20131238.","journal-title":"Br J Cancer"},{"key":"BFejhg2014161_CR41","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","volume":"297","author":"JN Weitzel","year":"2007","unstructured":"Weitzel JN, Lagos VI, Cullinane CA et al: Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007; 297: 2587\u20132595.","journal-title":"JAMA"},{"key":"BFejhg2014161_CR42","unstructured":"National Institute for Health and Care Excellence. CG164 Familial breast cancer: NICE guidance. Available at: \n                    http:\/\/guidance.nice.org.uk\/CG164\/NICEGuidance\/pdf\/English\n                    \n                  , 2013, (last accessed on 26 June 2014)."}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ejhg2014161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg2014161","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ejhg2014161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:11:41Z","timestamp":1684429901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ejhg2014161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFejhg2014161"],"URL":"https:\/\/doi.org\/10.1038\/ejhg.2014.161","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,20]]},"assertion":[{"value":"28 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}